A Preliminary Study of Deep-Learning Algorithm for Analyzing Multiplex Immunofluorescence Biomarkers in Body Fluid Cytology Specimens

Weibo Yu  Elizabeth Rao  Curtis D. Chin  Josephine S. Aguilar-Jakthong  Yunfeng Li  Christine Chow  Shu Yu (Grace) Wang  Jianyu Rao

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles (UCLA), Los Angeles, CA, USA

Keywords
Deep-learning algorithm · Multiplex immunofluorescence · Biomarkers

Abstract
Introduction: Multiplex biomarker analysis of cytological body fluid specimens is often used to assist cytologists in distinguishing metastatic cancer cells from reactive mesothelial cells. However, evaluating biomarker expression visually may be challenging, especially when the cells of interest are scant. Deep-learning algorithms (DLAs) may be able to assist cytologists in analyzing multiple biomarker expression at the single cell level in the multiplex fluorescence imaging (MFI) setting. This preliminary study was performed to test the feasibility of using DLAs to identify immunofluorescence-stained metastatic adenocarcinoma cells in body fluid cytology samples. Methods: A DLA was developed to analyze MFI-stained cells in body fluid cytological samples. A total of 41 pleural fluid samples, comprising of 20 positives and 21 negatives, were retrospectively collected. Multiplex immunofluorescence labeling for MOC31, BerEP4, and calretinin, were performed on cell block sections, and results were analyzed by manual analysis (manual MFI) and DLA analysis (MFI-DLA) independently. Results: All cases with positive original cytological diagnoses showed positive results either by manual MFI or MFI-DLA, but 2 of the 14 (14.3%) original cytologically negative cases had rare cells with positive MOC31 and/or BerEP4 staining in addition to calretinin. Manual MFI analysis and MFI-DLA showed 100% concordance. Conclusion: MFI combined with DLA provides a potential tool to assist in cytological diagnosis of metastatic malignancy in body fluid samples. Larger studies are warranted to test the clinical validity of the approach.

Introduction

Distinguishing metastatic adenocarcinoma from reactive mesothelial cells in body fluid cytology can be challenging. Diagnoses often require the assistance of immunohistochemical (IHC) staining for a battery of biomarkers, including biomarkers for mesothelial cells and markers for metastatic malignant glandular epithelial cells. Since IHC-based staining is usually performed 1 biomarker at a time and involves multiple cell block sections, it is often difficult to align the staining pattern of
biomarkers on cells of interest. This is especially problematic in cases with limited cellularity for evaluation.

One potential solution is multiplex fluorescence imaging (MFI) analysis, which allows simultaneous detection of up to 7 targets with quantification capabilities at high resolution on a single cell basis [1, 2]. This approach has been shown to be applicable in a variety of tissue-based settings. However, visual scoring of multiple biomarkers, particularly in a cell block section, can be challenging and time-consuming.

The development of an image-based automatic analytical system that can determine the expression of multiple biomarkers with greater objectivity and reproducibility, and alleviate the burden on pathologists to make challenging and time-consuming assessments, may have significant clinical implications. Deep-learning combined with digital technologies have potential for performing objective, quantitative assessments for biomarker analysis in the single-cell level [3, 4]. These deep-learning approaches use artificial convolutional neural networks, which can be trained directly from primary data without significant pathologist guidance on annotating morphologic or cytologic features. Studies comparing deep-learning based digital image analysis against manual biomarker assessment have been performed in subtyping breast cancer [5], measuring PD-L1 expression in non-small cell lung cancer [6], and scoring tumor infiltrating lymphocytes in tumor areas [7], with deep-learning methods showing superiority or at least non-inferiority to manual scoring with respect to accuracy and reproducibility.

Here, we present the development of a digital image-based deep-learning algorithm (DLA) for analyzing biomarkers in MFI settings (MFI-DLA). In particular, we report the feasibility of performing DLA on cell block sections of pleural fluid samples.

**Methods**

**Sample Collection**

We retrospectively and randomly selected 41 out of a total of 864 pleural fluid cytology specimens from archived cell block samples between 2015 and 2018. Of the 41 pleural fluid specimens selected, 20 were malignant and 21 were benign. All samples were collected in the cytology laboratory at University of California, Los Angeles (UCLA). Patient primary histological and cytology diagnosis were recorded for the analysis. Cases with an equivocal cytology diagnosis (atypical or suspicious) were not included in the study. The study was exempt from UCLA’s Institutional Review Board assessment as archived cell blocks were used and no patient identifiers were recorded.

**Cell Block Preparation**

Pleural effusion samples were each centrifuged at 2,500 rpm for 10 min. Supernatant fluid was discarded and the cell pellet transferred to a 1.5-mL centrifugation tube. One drop of warmed agar was added to each pellet and the samples were quickly agitated. Clots formed within 30–60 s and each sample was subsequently placed in a tissue cassette and processed as routine histology samples.

**Multiplex IHC Staining of MOC31, BerEP4, and Calretinin**

The paraffin slides were stained using the Opal™ Multiplex IHC Kit (Akoya Biosciences), which utilizes a sequence of antibody-antigen binding, fluorescence staining using HRP-conjugated secondary antibody, and heat-mediated removal of the target-binding complex for subsequent targeting of a different antigenic biomarker. In addition to the greater degree of multiplexing, this kit allows for compatibility with unlabeled primary antibodies, reduced cross-reactivity between antibodies, and no limitations with species compatibility by virtue of serial biomarker staining.

Briefly, cell block sections were dewaxed with xylene, rehydrated with a series of ethanol solutions, and washed. Antigen retrieval was performed using microwave treatment (45 s at 100% power, then additional 15 min at 20% power) with AR buffer (AR6 or AR9, Akoya Biosciences), then the slides were blocked, cooled, and washed with distilled water and TBST. Slides were incubated with primary antibodies specific to calretinin (Invitrogen, Cat#:180211, 1:100 dilution), Moc31 (Dako, #M3525, 1:200 dilution), and BerEP4 (Dako, #M0804, 1:200 dilution). Slides were then incubated with secondary anti-rabbit HRP-conjugated antibody (Dako envision, #K4003) or anti-mouse HRP-conjugated antibody (Dako envision, #K4001). Then a signal amplification of Opal fluorophore (1:100 dilution at room temperature for 10 min), followed by additional microwave treatment (45 s at 100% power, then additional 15 min at 20% power) between each antibody staining, and a final application of DAPI counterstain (1:2,000 dilution for 5 min) was performed. The fluorophores used were Opal 520 FITC for calretinin; Opal 570 TRITC for Moc31; and Opal 650 CY5 for BerE4. Fluorescence image exposure times are as follows: DAPI: 3.977 ms, FITC (OPAL 520): calretinin 37.27 ms, Cy3 (OPAL 570): MOC31 35.856 ms, and Cy5 (OPAL 690): BerEP4 39.09 ms. The images were then scanned at >20 magnification (Vectra Polaris, Akoya) and uploaded to a secure UCLA file share system.

**Visiopharm APP Development for Analyzing Biomarkers in Multiplex Settings**

We designed the multiplexed biomarker analysis protocol (APP) with Visiopharm, a company that specializes in developing image analysis software using DLA (https://www.visiopharm.com). The APP was designed to allow biomarker combinations to be analyzed, provided that the panels (1) used DAPI nuclei stain to highlight nucleated cells, (2) included a total of 4 stains, (3) used identical fluorophores (FITC, TRITC, CY5, and DAPI), and (4) scanned each fluorophore channel in the order performed for images on the training dataset. In addition, while the APP was initially validated on whole ovarian tissue slides cut from formalin-fixed paraffin embedded tissue blocks, the APP has the capability of evaluating multiplexed biomarker expression on cytology specimen preparations such as aspirate smears, cytospins, and cell blocks, so long as the above criteria are met. The APP was also partitioned into several “sub-protocols,”...
A significant challenge in developing DLA is curating a high-quality training dataset. Traditionally, this training dataset relies on H&E and multiplex IF stains on serial sections. This separation was implemented to allow the end-user to select functions based on the clinical situation and avoid wasting time on computational tasks that were not needed.

Fig. 1. Schematic of overall process for developing DLA for MFI analysis on sections. DLA, deep-learning algorithm; MFI, multiplex fluorescence imaging.

Fig. 2. The process of how positivity for metastatic tumor cells based on MOC31 and BerEP4 was determined by DLA (Visiopharm APP) with an example of a positive case of the study. All images shown were taken at 20× magnification.

After MFI staining, the entire field of cell block section was scanned at 20× magnification and uploaded for Visiopharm APP analysis (detail please see the Method section of the manuscript). A representative field of cell block section all four fluorophores was showing here.

The APP first defined nucleated cells (DAPI) to identify cells of interest

Next, the expression of Calretinin, Moc31, and BerEP4 on identified nucleated cell was determined. Upper image: cells with blue (DAPI), Green (FITC, opal 520, Calretinin), and Yellow (Cy3, opal 570, MOC31) fluorophores, and lower image: cells with blue (DAPI) and red (Cy5, opal 690, BerEP4) fluorophores

Called for positivity based on the presence of nucleated cells with both MOC31 (Yellow, Cy3, opal570) and BerEP4 (Red, Cy5, opal 690) expression of cells (indicated by arrowhead)
Deep-Learning Algorithm for Multiplex Biomarker Analysis

Interpretation of Results and Statistical Analysis

Manual MFI and MFI-DLA used the same criteria to determine if the specimen was “positive” or “negative” for metastatic malignancy: if there were cells which stained positive for MOC31 and/or BerEP4 and negative for calretinin, then the specimen was scored positive. Otherwise, the specimen was considered negative. Cells which stained positive for calretinin (green fluorescence) with additional MOC31 (yellow fluorescence) and/or BerEP4 (red fluorescence) positivity were considered equivocal. MFI analysis was carried out 6 months after manual MFI analysis as a washout period. Diagnoses from visual scoring and DLA scoring were compared with patient’s primary diagnosis and cytology diagnosis. Final results were confirmed by 2 pathologists (J.A.J. and J.Y.R.).

Interpretation of Results and Statistical Analysis

Table 1. Primary cytology diagnosis and the results of MFI visual analysis and MFI-DLA analysis

| Cytology diagnosis          | MFI biomarker staining | MFI results | MFI-DLA results |
|----------------------------|------------------------|-------------|-----------------|
|                            | calretinin            | MOC31/BerEP4|                 |
| 1 Adenocarcinoma           | Negative               | Positive    | Positive        |
| 2 Adenocarcinoma           | Negative               | Positive    | Positive        |
| 3 Adenocarcinoma           | Negative               | Positive    | Positive        |
| 4 Adenocarcinoma           | Negative               | Positive    | Positive        |
| 5 Adenocarcinoma           | Positive               | Positive    | Positive        |
| 6 Adenocarcinoma           | Negative               | Positive    | Positive        |
| 7 Adenocarcinoma           | Positive               | Positive    | Positive        |
| 8 Adenocarcinoma           | Positive               | Positive    | Positive        |
| 9 Adenocarcinoma           | Positive               | Positive    | Positive        |
| 10 Adenocarcinoma          | Positive               | Positive    | Positive        |
| 11 Adenocarcinoma          | Positive               | Positive    | Positive        |
| 12 Adenocarcinoma          | Positive               | Positive    | Positive        |
| 13 Adenocarcinoma          | Positive               | Positive    | Positive        |
| 14 Adenocarcinoma          | Positive               | Positive    | Positive        |
| 15 Adenocarcinoma          | Negative               | Positive    | Positive        |
| 16 Adenocarcinoma          | Negative               | Positive    | Positive        |
| 17 Adenocarcinoma          | Positive               | Positive    | Positive        |
| 18 Supportive of carcinoma | Positive               | Positive    | Positive        |
| 19 Adenocarcinoma          | Positive               | Positive    | Positive        |
| 20 Adenocarcinoma          | Positive               | Positive    | Positive        |
| 21 Negative                | Positive               | Negative    | Negative        |
| 22 Reactive changes        | Positive               | Negative    | Negative        |
| 23 Negative                | Positive               | Negative    | Negative        |
| 24 Negative                | Positive               | Negative    | Negative        |
| 25 Negative                | Positive               | Negative    | Negative        |
| 26 Reactive changes        | Positive               | Negative    | Negative        |
| 27 Negative                | Positive               | Negative    | Negative        |
| 28 Negative                | Positive               | Negative    | Negative        |
| 29 Negative                | Positive               | Negative    | Negative        |
| 30 Negative                | Positive               | Negative    | Negative        |
| 31 Negative                | Positive               | Negative    | Negative        |
| 32 Negative                | Positive               | Negative    | Negative        |
| 33 Negative                | Positive               | Positive    | Equivocal       |
| 34 Negative                | Positive               | Positive    | Equivocal       |

DLA, deep-learning algorithm; MFI, multiplex fluorescence imaging.
Results and Discussion

A total of 41 cases of pleural fluids, of which 20 were malignant and 21 were benign, were selected for the study. Seven of the 21 benign cases were noted to have only red blood cells on the cell blocks. These cases were excluded, leaving a total of 14 benign cases. The analysis process and staining patterns of MOC31, BerEP4 and calretinin are shown in Figure 2. DLA scoring generated the same results as the visual scoring (100% concordance, Table 1). While all cases with positive original cytological diagnoses showed positive visual MFI and MFI-DLA scores, 2 of the 14 (14.3%) original cytologically negative cases had rare calretinin positive cells that also stained positive for MOC31 and/or BerEP4. These 2 cases were considered “equivocal” by MFI and MFI-DLA analysis.

While initially validated on histological sections, the APP was designed with enough flexibility for analyzing cytology specimens with different cell markers expressed on heterogeneous cell populations. Here, we reported the results of DLA scoring for analyzing biomarkers in a multiplex immunofluorescence setting. Although only 34 cases were included in final analysis, our study demonstrated the feasibility of MFI-DLA analysis with complete (100%) concordance with manual MFI analysis.

It is interesting that 2 of the original cytologically negative cases had rare cells with MOC31 and/or BerEP4 positivity. This is not surprising as neither MOC31 nor BerEP4 antibody are 100% specific for identifying metastatic adenocarcinoma. MOC31 and BerEP4 expression may be seen in cases of reactive mesothelial cells at frequencies up to 13 and 10%, respectively [8, 9]. Albeit there were occasional nonspecific expressions of MOC31 or BerEP4 in mesothelial cells, a significant finding of 100% concordance between the manual score and DLA score was noted. These findings highlight the potential application of MFI-DLA in determining metastatic malignancies in body fluid cytological specimens.

Another interesting finding was the variable cellularity across the entire dataset; Figure 2 shows a typical positive case. In this study, the percentage of positive tumor cells in relation to mesothelial cells was not measured as it did not affect/contribute the outcome (positive or negative for tumor cells), though we acknowledge that this would be interesting to characterize in a future study.

While the preliminary study demonstrated the potential application of our MFI-DLA in differentiating metastatic malignancy versus benign pleural fluid samples, this approach may be useful in other settings important for diagnosis and management of cancer, such as quantifying PD-L1, Her-2, P16, and Ki-67 expression in single-cell levels. In fact, the program was developed initially for the analysis of PD-L1 in MFI setting. However, carefully designed studies will be needed to validate the value of MFI-DLA in actual clinical settings.

In conclusion, it is feasible to perform MFI-DLA analysis on cell block sections from body fluid samples. While most DLA methods have been validated on histology specimens, there may also be value in applying these tools to cytology specimens in clinical settings where fluids and cellular aspirates are more accessible and convenient to obtain. However, the actual clinical utility of this approach remains to be determined in additional studies with larger sample sizes.

Acknowledgements

We thank Sarah Holm Jørgensen from Visiopharm for technical expertise and support in APP development.

Statement of Ethics

The project received exemption from Institutional Review Board for human research subjects at UCLA.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

Project funded internally by the research fund of Department of Pathology and Laboratory Medicine, UCLA.

Author Contributions

Jianyu Rao conceptualized the study. Curtis Chin worked with Visiopharm to develop MFI-DLA program, Josephine S. Aguilar-Jakthong and Yunfeng Li prepared the cases and performed the stains and manual analysis. Weibo Yu performed MFI-DLA analysis. Elizabeth Rao, Christine Chow, and Grace Wang were student volunteers in Jianyu Rao’s group who worked with Weibo Yu virtually to carry out MFI-DLA analysis and manuscript preparation.
References

1 Viratham Pulsawatdi A, Craig SG, Bingham V, McCombe K, Humphries MP, Seneviratne S, et al. A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment. Mol Oncol. 2020 Oct;14(10):2384–402.

2 Tan WCC, Nerurkar SN, Cai HY, Ng HHM, Wu D, Wee YTF, et al. Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Commun. 2020;40(4):135–53.

3 Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology: new tools for diagnosis and precision oncology. Nat Rev Clin Oncol. 2019;16(11):703–15.

4 Niazi MKK, Parwani AV, Gurcan MN. Digital pathology and artificial intelligence. Lancet Oncol. 2019;20(5):e253–61.

5 Stalhammar G, Fuentes Martinez N, Lippert M, Tobin NP, Molholm I, Kis L, et al. Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod Pathol. 2016;29(4):318–29.

6 Kapil A, Meier A, Zuraw A, Steele KE, Rebellatto MC, Schmidt G, et al. Deep semi supervised generative learning for automated tumor proportion scoring on NSCLC tissue needle biopsies. Sci Rep. 2018;8(1):17343.

7 Klauschen F, Müller KR, Binder A, Bockmayr M, Hägele M, Seegerer P, et al. Scoring of tumor-infiltrating lymphocytes: from visual estimation to deep learning. Semin Cancer Biol. 2018;52(Pt 2):151–7.

8 Arora R, Agarwal S, Mathur SR, Verma K, Iyer VK, Aron M. Utility of a limited panel of calretinin and Ber-EP4 immunocytochemistry on cytospin preparation of serous effusions: a cost-effective measure in resource-limited settings. Cytojournal. 2011;8:14.

9 Kundu UR, Krishnamurthy S. Use of the monoclonal antibody MOC-31 as an immunomarker for detecting metastatic adenocarcinoma in effusion cytology. Cancer Cytopathol. 2011;119(4):272–8.